Geistlich Franchise has an incredible history spanning more than twenty years, constantly evolving and pioneering developments in its biomaterials. The company’s Jubilee Anniversary Celebration aims at providing more platforms where collaborative dental proponents will share their regenerative expertise and success. Geistlich has already established a website to cater for the above need, wherein dental professionals in the global dental/clinical practice exchange ideals, experiences and case studies of successful use of the enterprise’s biomaterials.
Geistlich Pharma Corporation continues to set the trend in regenerative dental practice with its superb collection of predictable and proven biomaterials, such as bone complements Geistlich Bio-Oss and Collagen, the resorb bilayer membrane, Geistlich Bio-Gide and the soft tissue collagen matrix, Geistlich Mucograft.
To date, the franchise has overseen well over one thousand publications demonstrating efficacious clinical practice from hundreds of practitioners. The conclusion of the franchise’s Jubilee year will assess and award contributions to their website, with prices including Apple iPads pre-installed with Geistlich’s Patient Info Package on Regenerative dentistry.
The Indo-Japanese academic institute, Nichi-in Centre for Regenerative Medicine (NCRM) intends to initiate a training program for regenerative medicine proponents by September this year.
Dr. Samuel Abraham, director of NCRM, mentions that the higher study course has already guaranteed partnerships and support from four universities across US and Canada; McMaster University, University of Ottawa, University of Toronto and Queen’s University in Canada. To participate in the program, NCRM is already reviewing applications from scientific scholars.
Regenerative medicine is an evolving domain that seeks to offer solutions to incurable diseases via the use of regeneration capable cells. Without a doubt, constant upgrading is requisite, and therefore a need for continuous integration between basic and translational science arises. NCRM plans to cater for the above concern through their web-based training program which serves as a platform where dental clinicians/scientists share ideals. Forums and lectures will be facilitated via webcast from the Toronto University in Canada.
The National Institute of Dental and Craniofacial Research recently awarded Drs. Seiichi Yamano and Brian Schmidt a $1.2M grant to perform tests on the effectiveness and safety of their non-viral gene delivery method catering for oral cancer patients. Brian L. Schmidt, Professor in the Department of Oral and Maxillofacial Surgery at New York University, mentions that oral cancer patients more often lead dismal lives. Due to the severe pain they experience, the patients find it difficult to eat, drink or talk. Doctors are therefore left with no other choice but to prescribe opioid induced medications, which in turn generate dire side effects further affecting these patients.
Seiichi Yamano, Associate Professor in the Department of Prosthodontics at NY University Dentistry, notes that gene therapy is emerging as a capable alternative to opioid use in the cancer pain treatment. The approach intends to negate oral cancer pain via the reversal of epigenetic changes, to in turn disrupt nociceptive signaling with less off-target impacts.
Ortek Therapeutics Inc., a global conglomerate in the oral bio-technology domain, was recently awarded a US patent on its ECD dental device. The gadget is a system capable of discerning early/pre-cavity decay, which proved to be difficulty via x-ray or visual examination. Laboratory tests on humans have shown that the ECD device can detect initial stages of tooth decay or oral demineralization with 100% accuracy.
In most cases, the back teeth are often more susceptible to tooth decay, and therefore the device is designed to cater for pre-cavity lesions in molars and premolars. The teeth’s biting surface have deep grooves that reveal tooth mineral loss in case of acid attacks responsible for cavity development. With demineralization or fracture, the tooth enamel becomes electrically conductive as the dentinal fluid on the enamel site completes a circuit with battery powered ECD device. The gadget incorporates a probe tip which accurately measures the amount of dentinal fluid seepage (the more the fluid, the greater the pre-cavity lesion). The data obtained could assist dental practitioners to assess the both severity and appropriate treatment of any lesions with minimal invasive care.